SeaStar Medical Secures Critical Billing Codes for AKI Therapy, Unlocking $4.5B Adult Market Potential
ICU sits 59% above its 52-week low of $2.07.
Summary
SeaStar Medical has obtained dedicated ICD-10-PCS codes for its Selective Cytopheretic Device (SCD) therapy for Acute Kidney Injury (AKI). These codes are crucial for standardized inpatient hospital billing and reimbursement, removing a significant commercial barrier. This development is particularly important for the potential launch of the SCD therapy in the adult AKI market, which the company estimates to be approximately $4.5 billion, significantly larger than its current pediatric market. The new codes are expected to take effect on October 1, 2026.
At the time of this announcement, ICU was trading at $3.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $2.07 to $12.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.